We evaluated the in vitro antianaerobic activity of razupenem (SMP-601, PTZ601), a new parenterally administered carbapenem, against 70 reference strains and 323 clinical isolates. Razupenem exhibited broadspectrum activity against anaerobes, inhibiting most of the reference strains when used at a concentration of <1 g/ml. Furthermore, it exhibited strong activity, comparable to those of other carbapenems (meropenem and doripenem), against clinically isolated non-fragilis Bacteroides spp. (MIC 90 s of 2 g/ml), with MIC 90 values of 0.06, 0.03, and 0.5 g/ml against Prevotella spp., Porphyromonas spp., and Fusobacterium spp., respectively. Clinical isolates of anaerobic Gram-positive cocci, Eggerthella spp., and Clostridium spp. were highly susceptible to razupenem (MIC 90 s, 0.03 to 1 g/ml).
Most anaerobic infections are polymicrobial, involving both aerobes and anaerobes. Escherichia coli, Staphylococcus aureus, and Enterococcus spp. are common aerobic bacteria concomitantly detected in intra-abdominal anaerobic infections. Razupenem (also known as SMP-601, PTZ601, PZ-601, or SM-216601) is a new parenterally administered carbapenem that exhibits broad-spectrum activity against various aerobic bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae, vancomycin-resistant Enterococcus faecium (VREF), ampicillin-resistant Haemophilus influenzae, and extended-spectrum ß-lactamase (ESBL)-producing bacteria (6, 8) . Pharmacokinetic studies of mice and humans (9, 10) indicated that razupenem showed a longer half-life than imipenem and meropenem (8) . Furthermore, razupenem has exhibited therapeutic effects against VREF, MRSA, and vancomycin-intermediate Staphylococcus aureus in a murine model of neutropenic thigh infection and a model of hematogenous murine bronchopneumonia (2, 5), respectively. There have also been reports on its potent activity against the anaerobe Bacteroides fragilis and Peptostreptococcus spp. (8) but no reports on such activity against other anaerobic species. Therefore, we evaluated the in vitro activity of razupenem against various reference strains and clinical isolates of anaerobic bacteria.
We studied a total of 70 Gram-positive and Gram-negative reference strains (63 species belonging to 26 genera) of anaerobic bacteria and some fastidious microaerophilic anaerobes. The reference strains included some characteristic clinical strains obtained from GAI (the culture collection center of our laboratory) and strains obtained from the American Type Culture Collection (ATCC), Deutsche Sammlung von Mikroorganismen (DSM), Japan Collection of Microorganisms (JCM), National Collection of Type Cultures (NCTC), and Virginia Polytechnic Institute and State University (VPI). We also studied 323 clinical strains isolated from various sources (including patients with infections of the abdomen, head and neck space, pleuropulmonary areas, skin, and soft tissue) between 2000 and 2007. The isolates were identified by standard criteria (3, 4, 7) .
The following antimicrobial agents were obtained from their respective manufacturers in the form of powders of known potency for use in this study: razupenem and meropenem from Dainippon Sumitomo Pharma, Co., Ltd., Osaka, Japan; panipenem from Daiichi Sankyo Co., Ltd., Tokyo, Japan; and doripenem, and metronidazole from Shionogi & Co., Ltd., Osaka, Japan.
The MICs were determined by an agar dilution method, as per document M11-7 of the Clinical and Laboratory Standards Institute (1). Brucella HK agar (Kyokuto Pharmaceutical Industrial Co., Ltd., Tokyo, Japan), which contains hemin (10 g/ml) and vitamin K 1 (10 g/ml) and thus supports the growth of fastidious anaerobes, was supplemented with 5% laked sheep blood and used as the test medium. The test strains were inoculated onto this medium at a density of 10 5 CFU per spot and incubated at 35°C in an anaerobic chamber (82% N 2 , 10% CO 2 , and 8% H 2 ). B. fragilis ATCC 25285, Bacteroides thetaiotaomicron ATCC 29741, and Eggerthella lenta ATCC 43055 were used for quality control.
Susceptibility tests were performed on the reference strains (Table 1 ). Razupenem exhibited potent activity against Grampositive anaerobic reference species, with MICs (Յ0.015 to 2 g/ml) that were comparable to those of other carbapenems tested and superior to those of metronidazole (Table 1) . Furthermore, when used at a concentration of Յ1 g/ml, razupenem inhibited most of the Gram-negative reference strains, except for five strains of B. fragilis, including two multidrug-resistant carbapenemase (CfiA)-producing strains (MIC of Ͼ128 g/ml for strains GAI30079 and GAI30144) ( Table 1) .
The in vitro activities of razupenem and the reference agents against the clinically isolated strains, expressed in terms of the MIC range, MIC 50 , and MIC 90 , are shown in to 0.5 and 0.5 to 2 g/ml, respectively). Razupenem exhibited strong activity, comparable to those of other carbapenems, against non-fragilis Bacteroides spp., which are often detected in abdominal surgical infection (MIC 50 and MIC 90 of razupenem of 0.25 to ϳ0.5 and 2 g/ml, respectively). Furthermore, the MICs of razupenem against Prevotella spp., Porphyromonas spp., and Fusobacterium spp., which are often isolated in infections of the head and neck space, pleuropulmonary areas, and abdomen, were comparable or superior to those of other antimicrobial agents (MIC 50 s and MIC 90 s of razupenem of Յ0.015 to 0.06 and 0.03 to 0.5 g/ml, respectively). Razupenem exhibited potent activity, comparable to that of other carbapenems, against clinical isolates of anaerobic Gram-positive cocci (GPC), with MIC 50 and MIC 90 values of Յ0.015 to 0.25 and 0.03 to 1 g/ml, respectively. Eggerthella spp. and Clostridium spp. were highly susceptible to razupenem (MIC 90 s of 0.03 to 1 g/ml). Carbapenems are not used to treat Clostridium difficile infections; nevertheless, razupenem exhibited the most potent activity among the antimicrobial agents tested in this regard, with MIC 50 and MIC 90 values of 0.25 and 0.5 g/ml, respectively.
This study revealed the broad-spectrum in vitro activity of razupenem against Gram-positive and Gram-negative anaerobic bacteria. This agent exhibited potent activity, comparable to those of other carbapenems, against most of the important clinical isolates tested. Previous in vitro data and our present findings suggest the potential role of razupenem in treating polymicrobial anaerobic infections. Unfortunately, however, Parabacteroides distasonis (n ϭ 6), B. uniformis (n ϭ 3), B. vulgatus (n ϭ 3), B. caccae (n ϭ 2), B. stercoris (n ϭ 1), and Odoribacter splanchnicus (n ϭ 1).
c Porphyromonas spp. (n ϭ 25): P. asaccharolytica (n ϭ 18), P. gingivalis (n ϭ 5), and P. uenonis (n ϭ 2). on August 15, 2017 by guest http://aac.asm.org/ development of razupenem has been discontinued in the United States. Therefore, razupenem itself is a drug that may not be put to practical use in the future. However, our present findings may contribute to the development of other analogous agents.
